Synta Pharmaceuticals Corp. (MDGL) Stock Price Up 6.3%
Synta Pharmaceuticals Corp. (NASDAQ:MDGL) shares rose 6.3% on Tuesday . The stock traded as high as $8.86 and last traded at $8.65, with a volume of 53,917 shares. The stock had previously closed at $8.14.
The firm has a 50-day moving average of $0.00 and a 200-day moving average of $0.00.
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.